CalciMedica closed at $1.34 on Nov 4, down 8.50%, 96.0% below its 52-week closing high. Volume of 43.9K shares was 0.47× its 20-day average (below normal).
Split-adjusted performance: -9.7% over one month, -56.8% over six months, -91.0% over one year.
Short interest was 61.6K shares at the Oct 15 settlement, down 28.7% from the prior report (0.3% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CALCCalciMedica | $1.35 | −8.50% | −56.8% | — | — | — | $9.2M | |
| TPSTTempest Therapeutics | $0.4633 | −1.13% | −77.1% | — | — | — | $9.3M | Compare |
| CURXCuranex Pharmaceuticals | $5.80 | −6.30% | −17.7% | — | — | — | $9.1M | Compare |
| ACTUActuate Therapeutics | $0.3699 | +5.69% | −87.6% | — | — | — | $8.9M | Compare |
| MTVAMetaVia | $1.34 | +6.35% | −4.3% | — | — | — | $8.8M | Compare |
| INMInMed Pharmaceuticals | $1.75 | +4.17% | +140.9% | — | — | — | $9.6M | Compare |
| LTRNLantern Pharma | $0.5866 | −2.61% | −72.6% | — | — | — | $8.8M | Compare |
| GTBPGT Biopharma | $4.84 | −8.16% | −51.9% | — | — | — | $8.7M | Compare |
| TOVXTheriva Biologics | $0.1900 | +4.40% | −50.3% | — | — | — | $8.7M | Compare |
No recent articles focused on CalciMedica. 1 articles mention it in passing.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
